The mutation status of both IDH1 and IDH2 (IDH1/2) genes is an important prognostic factor of both LGG and GBM,6 being since 2016 one of the principal genomic factors in the new World Health Organization Classification of Central Nervous System Tumors.7 This evidence concerns the gene IDH1 and central nervous system cancer.